Fiorentino DF, Chung LS, Christopher-Stine L et al.
Stanford University, Stanford, CA, USA.
Arthritis Rheum 2013;65:2954–62.
Ben Parker’s review: It is well known that dermatomyositis (DM) is associated with an increased risk of malignancy around the time of diagnosis, and investigations directed at this risk are a key feature of the management of DM (Clin Exp Dermatol 2009;34:451–5). Many patients with DM have autoantibodies, and several research groups have described a number of novel autoantibodies in DM, including those against transcription intermediary factor-1γ (TIF-1γ) and the nuclear matrix protein NXP-2. Reliable serological markers of increased malignancy risk would assist the management of these patients.